中国高校科技期刊研究会第9次会员代表大会在北京召开，中宣部出版局副局长张怀海、教育部科学技术与信息化司一级巡视员张国辉等领导出席会议并发表..
英文简介：Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.中文简介：（来自Google、百度翻译）肿瘤免疫学涉及自然或治疗诱导的癌症识别，以及肿瘤发生，炎症和免疫监视之间的复杂相互作用。现在，我们创建了一个新的，备受瞩目的杂志《肿瘤免疫学》，专门研究肿瘤免疫学。最近的进展使抗癌免疫疗法的首次临床示范 (和FDA批准) 成为可能。人们也越来越怀疑，出乎意料的是，许多目前使用的化学治疗剂的功效取决于免疫效应物的积极作用。用一个激烈的比喻，应用成功的化疗 (或放射治疗) 方案的肿瘤学家已经利用免疫系统识别肿瘤特异性或肿瘤相关抗原并控制癌症 (干细胞) 细胞生长的能力，而没有意识到无形的帮助之手。结果，免疫生物标志物对于确定癌症的预后和预测化学疗法的疗效变得越来越重要。支持将常规抗癌疗法与免疫疗法相结合的理由也很充分。 肿瘤免疫学将在肿瘤免疫学的基础，转化和临床领域接受备受瞩目的论文。涉及实体或血液癌症，炎症，先天和后天免疫反应的提交将受到欢迎。
